Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 3Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1

Interventions

Pemetrexed 3Carboplatin 3HM781-36B 2Gemcitabine 2pembrolizumab 1osimertinib 1aumolertinib 1aflutinib 1Taxes 1Paclitaxel 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cisplatin 1Bortezomib 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC × aflutinib × Clear all
NCT02973763 2025-04-03

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Allist Pharmaceuticals, Inc.

Phase 1 Terminated
14 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡